Zydus Cadila receives tentative approval from USFDA for Brexpiprazole Tablets

Zydus Cadila has received tentative approval from the USFDA to market Brexpiprazole Tablets in the strength of 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, and 4 mg. (US RLD: Rexulti Tablets). Brexpiprazole is an atypical antipsychotic indicated for use as an adjunctive therapy to antidepressants for the treatment of Major Depressive Disorder (MDD) and for treatment of schizophrenia. The drug will be manufactured at the group's formulation manufacturing facility at the SEZ, Ahmedabad.

The group now has 321 approvals and has so far filed over 400 ANDAs since the commencement of the filing process in FY 2003-04.

Shares of Cadila Healthcare Ltd. was last trading in BSE at Rs. 555.55 as compared to the previous close of Rs. 553.55. The total number of shares traded during the day was 48034 in over 1322 trades.

The stock hit an intraday high of Rs. 558.1 and intraday low of 551.45. The net turnover during the day was Rs. 26660649.

Source : Equity Bulls

Keywords